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In yeast, worms, and flies, an extra copy of the gene
encoding the Sirtuin Sir2 increases metabolic effi-
ciency, as does administration of polyphenols like
resveratrol, thought to act through Sirtuins. But
evidence that Sirtuin gain of function results in in-
creased metabolic efficiency in mammals is limited.
We generated transgenic mice with moderate over-
expression of SirT1, designed to mimic the Sirtuin
gain of function that improves metabolism in C.
elegans. These mice exhibit normal insulin sensitivity
but decreased food intake and locomotor activity,
resulting in decreased energy expenditure. However,
in various models of insulin resistance and diabetes,
SirT1 transgenics display improved glucose toler-
ance due to decreased hepatic glucose production
and increased adiponectin levels, without changes
in body weight or composition. We conclude that
SirT1 gain of function primes the organism for meta-
bolic adaptation to insulin resistance, increasing he-
patic insulin sensitivity and decreasing whole-body
energy requirements. These findings have important
implications for Sirtuin-based therapies in humans.
INTRODUCTION
The increased prevalence of obesity and diabetes, with the at-
tendant increase in morbidity and mortality, pose a substantial
therapeutic challenge (Narayan et al., 2003). Genetic screens in
lower organisms provide evidence that gain-of-function of the
deacetylase Sir2 results in beneficial metabolic effects and life
span extension (Haigis and Guarente, 2006). Sirtuin agonists in-
crease metabolic efficiency in rodents through a mechanism
bearing similarity with calorie restriction (Baur et al., 2006;
Lagouge et al., 2006; Milne et al., 2007). However, the specificity
of these compounds remains undefined.
The function of mammalian Sir2a (also known as SirT1) in me-
tabolism is controversial. Two models of SirT1 gain of function in
either pancreatic b cells or adipocytes and brain result in im-
proved insulin secretion and sensitivity, respectively (BordoneCeet al., 2007; Moynihan et al., 2005). But increasing SirT1 expres-
sion in liver impairs glucose tolerance (Rodgers et al., 2005), and
resveratrol increases glucose production by hepatoma cells
(Frescas et al., 2005). Thus, it remains unclear whether chronic,
ubiquitous SirT1 activation ultimately benefits or impairs meta-
bolic control.
To address this question, we developed transgenic mice
designed to mimic the chromosomal duplication leading to the
moderate gain of function that improves metabolism in C.ele-
gans. In the latter organism, Sir2 function requires the FoxO1
ortholog daf-16 (Tissenbaum and Guarente, 2001). Thus, in our
studies we sought to address whether SirT1 gain of function
mediates its effects through FoxO1.
RESULTS
Generation and Analysis of SirT1 Transgenic Mice
To test the hypothesis that SirT1 participates in the regulation of
metabolism, we generated BAC transgenic mice overexpressing
SirT1 (SirT1 bacterial artificial chromosome overexpressor, Sir-
BACO). SirBACO mice were born in Mendelian ratios and dis-
played no gross anatomical or reproductive defects. SirT1 levels
were2- to 3-fold higher than control littermates, except in the
spleen (7-fold higher), and distribution patterns were indistin-
guishable from those of the endogenous protein in all tissues
examined (Figures 1A and 1B). SirT1 overexpression was pre-
served when SirBACO mice were backcrossed onto the db/db
background (Figure 1C). To probe the transgene’s function, we
intercrossed SirBACO with Sirt1/ mice (McBurney et al.,
2003). The transgene readily rescued developmental defects
and postnatal lethality of Sirt1/ mice (data not shown). These
findings are consistent the generation of a mouse model of
SirT1 gain of function.
Altered Energy Balance in SirBACO Mice
We carried out a metabolic characterization of SirBACOmice on
a standard diet. Serum metabolite levels—including insulin and
glucose—were normal (Table S1), as was the response to intra-
peritoneal glucose or insulin challenge tests (Figures 2A and 2B).
However, we detected a 30% increase in plasma adiponectin
levels (Table S1).
In C. elegans and D. melanogaster, increased Sir2 mimics the
effects of calorie restriction to extend life span (Haigis andll Metabolism 8, 333–341, October 8, 2008 ª2008 Elsevier Inc. 333
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decreases energy expenditure and increases metabolic effi-
ciency by decreasing O2 consumption (Fontana and Klein,
2007). To determine whether SirT1 overexpression reproduces
these subphenotypes, we carried out indirect calorimetry ex-
periments. SirBACO mice demonstrated a coordinate 15%
decrease in O2 consumption and CO2 production (Figure 2C;
data not shown). Due to the combined fall in VO2 and VCO2,
the respiratory quotient (RQ = VCO2/VO2) was unchanged
(Figure 2D). In addition, spontaneous locomotor activity de-
creased by 33.6% ± 1.4% (Figure 2E), more markedly during
the dark phase.
To investigate differences in basal metabolic rate, we com-
pared the energy expenditure required for locomotor activity
Figure 1. Expression Levels and Tissue
Distribution of Sirt1 in SirBACO Mice
(A) Western blot of SirT1 in mouse tissues.
(B) Immunohistochemistry of SirT1 in mouse brain;
DMH: dorsomedial hypothalamus; VMH: ventro-
medial hypothalamus; ARC: arcuate nucleus.
(C) SirT1 expression in SirBACO::db/db mice and
controls.
(Ravussin et al., 1986). SirBACO mice
had decreased resting energy expendi-
ture, but no differences at higher activity
levels (Figure S1). Body weight and com-
position were similar in SirBACO mice
and nontransgenic littermates (Figure 2F).
Food intake decreased by 15%± 1.3% in
SirBACO mice (Figure 2G), consistent
with the preservation of normal body
weight, in the face of decreased meta-
bolic rate and activity.
In response to 24 hr food deprivation
SirBACO mice showed a normal drop in
RQ, reflecting increased fat oxidation
(data not shown). These data indicate
that, although hypometabolic, SirBACO
mice have normal rates of fatty acid oxi-
dation. They also exhibited lower body
temperature than control littermates un-
der fed and fasted conditions (Figure 2H),
but did not display changes in blood pres-
sure or heart rate (Figure S2), suggesting
that the effect on body temperature is
secondary to decreased locomotion
(Weinert and Waterhouse, 1998).
SirBACO Mice Are Protected from
Insulin-Resistant Diabetes
We next asked whether SirT1 overex-
pression affects the susceptibility to
insulin resistance and diabetes in envi-
ronmental and genetic models of these
conditions.When SirBACOmice on an in-
bred C57BL/6J background were placed
on a high-fat diet or backcrossed onto
db/dbmice, they showed lower blood glucose and plasma insu-
lin levels (Figures 3A and 3B; Table S1) and better glucose toler-
ance (Figure 3C) than nontransgenic controls, despite similar
body weight (Figure S3A), weight gain during the diet
(Figure 3D), and body fat content (Figure 3E). We provisionally
conclude that SirT1 overexpression does not improve glucose
tolerance per se, but prevents the adverse effects of obesity
on glucose metabolism.
Catalytically Inactive SirT1 Fails to Protect Aging Mice
from Glucose Intolerance
To assess the specificity of these findings, we carried out
glucose tolerance tests in aging transgenic mice expressing
a catalytically inactive SirT1 transgene (H355Y) (Luo et al.,
334 Cell Metabolism 8, 333–341, October 8, 2008 ª2008 Elsevier Inc.
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(A and B) Intraperitoneal glucose tolerance tests and (B) insulin tolerance tests in 4-month-old mice on standard diet (n = 9–11 each).
(C–E) Oxygen consumption (VO2), (D) respiratory quotient (RQ), and (E) locomotor activity in 8-week-old mice over 24 hr (line chart) and mean 24 hr values
(bar graphs) in WT (full bars) and SirBACO mice (empty bars) (n = 7–8 each).
(F) Body weight of chow-fed, 4-month-old mice (n = 10–11 each).
(G) 24 hr food intake (n = 9–11).
(H) Body temperature in fed and 24 hr-fasted mice (n = 9–12 each). * = p < 0.05. Error bars represent ± SEM.
Cell Metabolism 8, 333–341, October 8, 2008 ª2008 Elsevier Inc. 335
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no differences in glucose tolerance from control littermates,
demonstrating that SirT1 catalytic activity is required for its insu-
lin-sensitizing effects (Figure S3B).
Normal Energy Expenditure in Diabetes-Resistant
SirBACO Mice
Based on the decrease of food intake and energy expenditure in
SirBACOmice, we wanted to determine whether the transgene’s
ability to improve glucose homeostasis in diabetes models could
be explained by changes in physical activity or metabolic rate. In
both the high-fat diet and db/dbmodel of insulin-resistant diabe-
tes, body weight and composition were similar between SirT1
transgenic and nontransgenic mice (Figures 3D and 3E). In con-
trast to the findings in SirBACO mice on a normal diet (Figure 2),
there were no differences in metabolic rate, spontaneous loco-
motor activity, or food intake in SirBACO mice on a high-fat
diet or crossed onto db/db compared to littermate controls
(Figures 3F and 3G; data not shown). We conclude that SirT1
promotes a state of increased energy efficiency that protects
against insulin resistance and hyperglycemia.
Hyperadiponectinemia and Increased Insulin Sensitivity
in SirBACO Mice on High-Fat Diet
To determine the mechanism of improved glucose tolerance in
SirBACO mice in a diabetes-predisposing background, we per-
formed hyperinsulinemic euglycemic clamps in high fat-fed and
in aging mice (12 months old). In both models, we detected
increased insulin-stimulated glucose disposal—as reflected by
a higher glucose infusion rate (GIR)—without changes in glucose
disappearance rates (Rd), when compared to controls (Figures
4A and S4). Moreover, insulin’s ability to suppress hepatic
glucose production rose by >30% in high fat-fed SirBACO
mice, relative to wild-type littermates (Figures 4B and S4). These
findings indicate that the improvement of glucose homeostasis is
due to increased hepatic insulin sensitivity (Accili, 2004).
The decrease in hepatic glucose production observed in
clamp studies could be due to increased insulin production, im-
proved insulin sensitivity, or both. However, plasma insulin levels
were lower in high fat-fed SirBACO and SirBACO::db/db mice
(Figure 3B), consistent with improved insulin sensitivity. Islet
b cell mass, b cell insulin content, and insulin secretion from iso-
lated pancreatic islets were nearly identical in SirBACO and con-
trol mice (Figure S5). Based on prior evidence that adiponectin
increases hepatic insulin sensitivity (Combs et al., 2001), we an-
alyzed the role of adiponectin in our transgenic model. Whereas
high fat feeding was associated with a modest decrease in
plasma adiponectin levels in wild-type mice, in SirBACO mice
we observed an 30%–40% rise (Figure 4C), suggesting that
the ability to prevent hyperglycemia is due to increased adipo-nectin synthesis/secretion, independent of differences in body
fat mass. In contrast, we found no differences in resistin, PAI-
1, TNF-a, or leptin levels (Table S1). To identify the source of in-
creased adiponectin levels, we measured adiponectin mRNA in
white adipose tissue (WAT) from mice fed either standard or
high-fat diets and observed a similar increase (Figure 4D).
Plasma adiponectin isoform distributionwas unchanged, with in-
creases in both the high and medium molecular weight compo-
nents (Figure 4E).
Adiponectin has been proposed to signal through at least two
receptors, AdipoR1 and AdipoR2, which activate AMPK and
PPARa, respectively (Yamauchi et al., 2003). Consistent with
the observed hyperadiponectinemia, high fat-fed and SirBA-
CO::db/db mice showed elevated phospho-AMPK levels in
WAT, liver, and skeletal muscle (Figures 4F and S6). Notably,
SirT1 appears to prevent the obesity-driven decrease in phos-
pho-AMPK levels (Martin et al., 2006). Furthermore, in high fat-
fed SirBACO mice we also found higher mRNA levels of Ppara
and its target genes,Cpt1 andAdipor2, in liver (Figure 4G). These
results are consistent with increased adiponectin signaling
through AdipoR1 and AdipoR2 and provide a potential mecha-
nism for the increase in hepatic insulin sensitivity.
FoxO1 Deacetylation Phenocopies the Effects of SirT1
Overexpression
Finally, we sought to delineate a mechanism linking SirT1 over-
expression to hyperadiponectinemia. Among SirT1 substrates,
the transcription factor FoxO1 promotes adiponectin expression
(Qiao and Shao, 2006) and FoxO1 haploinsufficiency decreases
adiponectin levels (Nakae et al., 2003). SirT1 deacetylates
FoxO1 at multiple sites, increasing FoxO1 transcriptional activity
(Kitamura et al., 2005). Indeed, acetyl-FoxO1 levels were
decreased in hepatocytes from SirBACO mice compared to
controls (Figure 4H), as were acetyl-Pgc1a levels in muscle
(Figure 4I).
To test the hypothesis that SirT1 and FoxO1 coordinately reg-
ulate adiponectin expression, we examinedAcrp30 (the gene en-
codingadiponectin) expression in adipocytes. As constitutive ac-
tivation of either FoxO1 or SirT1 inhibits adipocyte differentiation
(Nakae et al., 2003; Picard et al., 2004), we used 3T3-L1 CARD
cells, overexpressing the adenoviral receptor, to introduce ade-
noviruses encoding FoxO1 and SirT1 into differentiated adipo-
cytes (Orlicky et al., 2001). Wild-type FoxO1 increased Acrp30
by 40%. Similarly, SirT1 increased Acrp30 transcription in
a FoxO1-dependent manner (Figure 4J). Conversely, FoxO1
knockdown (Matsumoto et al., 2007) resulted in decreased
Acrp30 levels (Figure 4K). Expression of a mutant FoxO1
designed to mimic SirT1-mediated deacetylation (FoxO1-dAc)
increased Acrp30 expression, while a mutant FoxO1 mimicking
‘‘constitutive acetylation’’ (FoxO1-Ac) (Kitamura et al., 2005)Figure 3. SirT1 Increases Insulin Sensitivity in Obese Mice
(A and B) Fasting glucose and (B) insulin levels in SirBACO and WT mice in three conditions: 11-month-old on standard diet (aged), 5-month-old on HFD, or
8-week-old on db/db background.
(C) Glucose tolerance in 4-month-old SirBACO mice on HFD.
(D) Body weight in SirBACO (empty symbols) andWTmice (filled symbols) fed regular chow (n = 13–14 each), HFD (n = 12–16 each), or bred with db/db (n = 9–14
each).
(E–G) Fat mass, (F) indirect calorimetry, and (G) locomotor activity in db/db (full bars), high fat-fed WT (full bars) and SirBACO::db/db or HFD-fed SirBACO mice
(empty bars) (n = 5–8 each). * = p < 0.05, ** = p < 0.01. Error bars represent ± SEM.
Cell Metabolism 8, 333–341, October 8, 2008 ª2008 Elsevier Inc. 337
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indicate that FoxO1-dependent Acrp30 transcription can be reg-
ulated by SirT1-mediated deacetylation.
To assess the cell nonautonomous effects of SirT1 on liver
gene expression, we isolated primary hepatocytes from WT or
SirBACO mice and measured Foxo1/Pgc1a target genes. Con-
sistent with prior observations (Frescas et al., 2005; Rodgers
et al., 2005), we observed increased levels of G6pc, Pck1, and
Igfbp1 in response to cAMP (Figure 4L). The Ppara target
Fgf21 was also elevated in SirBACO hepatocytes but was not
regulated by cAMP (Figure 4L). These results indicate that the
cell-autonomous and nonautonomous actions of SirT1 on
hepatic glucose production are opposite. We speculate that cir-
culating factors account for the latter.
DISCUSSION
The ability of Sirtuin gain of function to extend life span and
improvemetabolism in simple organisms, together with the insu-
lin-sensitizing properties of Sirtuin agonists in rodents, have led
to the exploration of this pathway for therapeutic ends in meta-
bolic disease. But a rigorous genetic test of the hypothesis that
Sirtuin gain of function results in positive metabolic effects has
not been carried out.
Two models of SirT1 gain of function had previously been re-
ported. SirT1 overexpression in b cells increased insulin secre-
tion (Moynihan et al., 2005). SirBACO mice did not show this
phenotype, possibly due to differences in the levels of SirT1
expression. In SirT1 knockin mice (Bordone et al., 2007), the
transgene is expressed off the b-actin locus, leading potentially
to developmental effects that impair adipocyte differentiation
(Picard et al., 2004), and increase insulin sensitivity. Thus, the
SirT1 knockin model cannot distinguish between a direct effect
of SirT1 and an indirect one due to reduced body fat.
Complex Metabolic Effects of SirT1 Overexpression
Our results demonstrate complex and not easily generalizable
effects of SirT1 overexpression. In chow-fed mice, SirT1 gain
of function has no discernible effects on insulin sensitivity and
glucose utilization, but engenders a behavioral response that
partly mimics calorie restriction. While further studies will be re-
quired to dissect the site(s) of these Sirtuin effects, they are likely
to reflect an involvement of the central nervous system, and thus
point to the need for rigorous behavioral/psychometric testing in
early-phase clinical trials of Sirtuin agonists. In light of the current
prevalence of overweight, the effects of SirT1 to reduce food
intake in mice are of some interest vis-a`-vis the possibility of de-
veloping SirT1 agonists for use in human obesity. In the presentstudy, we cannot discern whether these effects are mediated di-
rectly in the central nervous system or by circulating factors.
Resveratrol-treated mice fed a high-fat diet display increased
O2 consumption (Lagouge et al., 2006) and decreased body
weight (Baur et al., 2006; Lagouge et al., 2006). SirBACO mice
on a high-fat diet do not display these phenotypes, but—similar
to resveratrol-treated mice—show decreased locomotor activity
(Lagouge et al., 2006). The data suggest that resveratrol acts on
additional Sirtuins or on different targets. While both exogenous
resveratrol and SirT1 overexpression improve glucose tolerance
in high fat-fed and db/db mice, the mechanisms appears to
differ: our studies point to a mechanistic link with hyperadipo-
nectinemia, while improved ATP utilization seems to protect
resveratrol-treated mice from diet-induced diabetes (Baur
et al., 2006; Lagouge et al., 2006). The hyperadiponectinemia
model allows us to reconcile the decreased hepatic glucose
production in SirBACO mice with SirT1’s ability to increase it
(Rodgers et al., 2005). We propose that, in SirBACOmice, the in-
sulin-sensitizing effect of adiponectin trumps SirT1’s cell-non-
autonomous activation of the gluconeogenic program.
In Vivo SirT1 Substrates and Metabolic Control
In C.elegans, the FoxO1 ortholog daf-16 is required for life-span
extension in response to SirT1 gain of function (Tissenbaum and
Guarente, 2001). The widespread role of FoxO1 in mammalian
metabolism provides a testable hypothesis on SirT1’s mecha-
nism of action. In this regard, we found that, unlike common
forms of obesity and type 2 diabetes (Hu et al., 1996), SirBACO
mice in diabetic and obese backgrounds display increased adi-
ponectin. We propose that SirT1 acts through FoxO1 to increase
adiponectin production. But given the conflicting results on the
effect of SirT1 on adiponectin expression (Qiang et al., 2007;
Qiao and Shao, 2006), the hyperadiponectinemia of SirBACO
mice may have heterogeneous causes, including changes in b-
adrenergic signaling or redox potential (Fasshauer et al., 2001;
Furukawa et al., 2004). Nonetheless, this phenotype bears simi-
larities with the effect of adiponectin overexpression in ob/ob
mice (Kim et al., 2007). Moreover, knockin mice bearing consti-
tutively deacetylated FoxO1 alleles mimic the energy balance
phenotype of SirBACO mice, supporting the contention that
the effects of SirT1 are mediated by FoxO1 (A.B. and D.A., un-
published data).
Conclusions
The ability of SirBACO mice to adapt their basal phenotype and
thus prevent insulin-resistant diabetes will rekindle the debate on
the evolutionary function of Sirtuins. SirT1 appears to function as
a ‘‘reverse thrifty gene’’ that protects against metabolic diseasesFigure 4. SirT1 Decreases HGP and Regulates Adiponectin
(A and B) Glucose infusion (GIR) and disappearance rates (Rd) and (B) insulin suppression of hepatic glucose production (HGP) in high fat-fed mice (n = 5–11
each).
(C and D) Plasma adiponectin (n = 11–13) and (D) WAT mRNA levels (Acrp30) in 16-week-old mice (8-week-old in the SirBACO::db/db cross).
(E) Plasma adiponectin isoform distribution.
(F) AMPK phosphorylation in WAT and liver.
(G) mRNA levels of adiponectin target genes (n = 4–5 each).
(H and I) FoxO1 acetylation in hepatocytes and (I) Pgc1a acetylation in gastrocnemius muscle.
(J and K) Regulation ofAcrp30 mRNA levels in 3T3-L1. * = p < 0.05, ** = p < 0.01.
(L) Gene expression in primary mouse hepatocytes (n = 4 each). Error bars represent ± SEM.
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expenditure in the physiologic state. The likely behavioral
aspects of SirT1 activation deserve closer scrutiny, if Sirtuin-
based approaches are to be introduced in the clinic.
EXPERIMENTAL PROCEDURES
Mice
We used BAC RP23-390D8 to generate SirBACO and SirT H355Y mice. Two
lines of WT SirT1 transgenics with similar expression levels (Figure S7) had
similar metabolic features (data not shown). db/+ m/+ were from Jackson
Laboratory. High-fat diet (60% of calories from fat) (Research Diets) was ad-
ministered from 4 to 20 weeks of age. All data are frommale mice backcrossed
at least 10 generations to C57BL /6J.
Antibodies and Cell Culture
Antibodies were from Affinity BioReagents (adiponectin), Cell Signaling Tech-
nologies (Acetyl lysine, phospho and total AMPK, and PGC-1a), Santa Cruz
Biotechnology (acetyl- and total-FoxO1), Upstate Biotechnology (Sir2, p85),
and Calbiochem (actin antibody JLA20). Culture and infection of 3T3-L1
CARD cells have been described (Ross et al., 2003).
Metabolic and Glucose Clamp Studies
We performed all assays as described (Lin et al., 2007; Matsumoto et al.,
2007).
Energy Balance
Indirect calorimetry was performed using LabMaster (TSE Systems). All mice
were acclimatized for 24 hr before measurements every 14 min for 96 hr. Rest-
ing metabolic rate was determined by generating average energy expenditure
and locomotor activity at each 14 min time point. Energy efficiency plots were
obtained as described (Ravussin et al., 1986). Food intake wasmeasured daily
for 2 weeks with feeding hoppers. Core body temperature was measured with
a probe (YSI Incorporated), blood pressure and heart rate with Hatteras
Instrument MC4000, and body composition with either Piximus DEXA scanner
(GE Healthcare) or NMR (Bruker Optics).
RNA and Protein Analysis
See Supplemental Data.
Adenovirus Generation
Adenovirus encoding constitutively acetylated (Foxo1-Ac), and deacetylated
mutants (Foxo1-dAc), or Foxo1-GFP were generated using previously
described cDNAs (Frescas et al., 2005; Kitamura et al., 2005), cloned into
AdEasy pShuttle-CMV (Stratagene). Other adenoviruses have been described
(Matsumoto et al., 2006).
Statistical Analysis
P values were calculated by unpaired Student’s t tests.
SUPPLEMENTAL DATA
Supplemental Data include seven figures, one table, Supplemental Experi-
mental Procedures, and Supplemental References and can be found online
at http://www.cellmetabolism.org/cgi/content/full/8/4/333/DC1/.
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